Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole primary therapy for invasive aspergillosis and rare mold infections in pediatric patients
2008-005275-10Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voriconazole in invasive aspergillosis (IA), allescheriosis, fusariosis and 1 more, sponsored by Pfizer. Primary endpoint: Safety and tolerability throughout the study including follow-up. Started Jan 2009; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive aspergillosis (IA)allescheriosisfusariosisInvasive Mold Infections (IMIs)
Beyond the preview
Go deeper on 2008-005275-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005275-10.